{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:52:17Z","timestamp":1791989537556,"version":"4.4.0"},"reference-count":439,"publisher":"National Institute for Health and Care Research","issue":"62","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["09\/46\/01"],"award-info":[{"award-number":["09\/46\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>End-stage renal disease is a long-term irreversible decline in kidney function requiring renal replacement therapy: kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation, followed by immunosuppressive therapy (induction and maintenance therapy) to reduce the risk of kidney rejection and prolong graft survival.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect\u00ae<\/jats:sup>, Novartis Pharmaceuticals UK Ltd) and rabbit anti-human thymocyte immunoglobulin (rATG) (Thymoglobulin\u00ae<\/jats:sup>, Sanofi) as induction therapy, and immediate-release tacrolimus (TAC) (Adoport\u00ae<\/jats:sup>, Sandoz; Capexion\u00ae<\/jats:sup>, Mylan; Modigraf\u00ae<\/jats:sup>, Astellas Pharma; Perixis\u00ae<\/jats:sup>, Accord Healthcare; Prograf\u00ae<\/jats:sup>, Astellas Pharma; Tacni\u00ae<\/jats:sup>, Teva; Vivadex\u00ae<\/jats:sup>, Dexcel Pharma), prolonged-release tacrolimus (Advagraf\u00ae<\/jats:sup>Astellas Pharma), belatacept (BEL) (Nulojix\u00ae<\/jats:sup>, Bristol-Myers Squibb), mycophenolate mofetil (MMF) (Arzip\u00ae<\/jats:sup>, Zentiva; CellCept\u00ae<\/jats:sup>, Roche Products; Myfenax\u00ae<\/jats:sup>, Teva), mycophenolate sodium (MPS) (Myfortic\u00ae<\/jats:sup>, Novartis Pharmaceuticals UK Ltd), sirolimus (SRL) (Rapamune\u00ae<\/jats:sup>, Pfizer) and everolimus (EVL) (Certican\u00ae<\/jats:sup>, Novartis) as maintenance therapy in adult renal transplantation.<\/jats:p><\/jats:sec>Methods<\/jats:title>Clinical effectiveness searches were conducted until 18 November 2014 in MEDLINE (via Ovid), EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of Science (via ISI), Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Health Technology Assessment (The Cochrane Library via Wiley Online Library) and Health Management Information Consortium (via Ovid). Cost-effectiveness searches were conducted until 18 November 2014 using a costs or economic literature search filter in MEDLINE (via Ovid), EMBASE (via Ovid), NHS Economic Evaluation Database (via Wiley Online Library), Web of Science (via ISI), Health Economic Evaluations Database (via Wiley Online Library) and the American Economic Association\u2019s electronic bibliography (via EconLit, EBSCOhost<\/jats:italic>). Included studies were selected according to predefined methods and criteria. A random-effects model was used to analyse clinical effectiveness data (odds ratios for binary data and mean differences for continuous data). Network meta-analyses were undertaken within a Bayesian framework. A new discrete time\u2013state transition economic model (semi-Markov) was developed, with acute rejection, graft function (GRF) and new-onset diabetes mellitus used to extrapolate graft survival. Recipients were assumed to be in one of three health states: functioning graft, graft loss or death.<\/jats:p><\/jats:sec>Results<\/jats:title>Eighty-nine randomised controlled trials (RCTs), of variable quality, were included. For induction therapy, no treatment appeared more effective than another in reducing graft loss or mortality. Compared with placebo\/no induction, rATG and BAS appeared more effective in reducing biopsy-proven acute rejection (BPAR) and BAS appeared more effective at improving GRF. For maintenance therapy, no treatment was better for all outcomes and no treatment appeared most effective at reducing graft loss. BEL\u2009+\u2009MMF appeared more effective than TAC\u2009+\u2009MMF and SRL\u2009+\u2009MMF at reducing mortality. MMF\u2009+\u2009CSA (ciclosporin), TAC\u2009+\u2009MMF, SRL\u2009+\u2009TAC, TAC\u2009+\u2009AZA (azathioprine) and EVL\u2009+\u2009CSA appeared more effective than CSA\u2009+\u2009AZA and EVL\u2009+\u2009MPS at reducing BPAR. SRL\u2009+\u2009AZA, TAC\u2009+\u2009AZA, TAC\u2009+\u2009MMF and BEL\u2009+\u2009MMF appeared to improve GRF compared with CSA\u2009+\u2009AZA and MMF\u2009+\u2009CSA. In the base-case deterministic and probabilistic analyses, BAS, MMF and TAC were predicted to be cost-effective at \u00a320,000 and \u00a330,000 per quality-adjusted life-year (QALY). When comparing all regimens, only BAS\u2009+\u2009TAC\u2009+\u2009MMF was cost-effective at \u00a320,000 and \u00a330,000 per QALY.<\/jats:p><\/jats:sec>Limitations<\/jats:title>For included trials, there was substantial methodological heterogeneity, few trials reported follow-up beyond 1 year, and there were insufficient data to perform subgroup analysis. Treatment discontinuation and switching were not modelled.<\/jats:p><\/jats:sec>Future work<\/jats:title>High-quality, better-reported, longer-term RCTs are needed. Ideally, these would be sufficiently powered for subgroup analysis and include health-related quality of life as an outcome.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Only a regimen of BAS induction followed by maintenance with TAC and MMF is likely to be cost-effective at \u00a320,000\u201330,000 per QALY.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42014013189.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta20620","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T12:28:01Z","timestamp":1472646481000},"page":"1-594","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model"],"prefix":"10.3310","volume":"20","author":[{"given":"Tracey","family":"Jones-Hughes","sequence":"first","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Snowsill","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Haasova","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Coelho","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Crathorne","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cooper","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mujica-Mota","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Peters","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Varley-Campbell","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Huxley","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Moore","sequence":"additional","affiliation":[{"name":"Exeter Kidney Unit, Royal Devon and Exeter Foundation Trust Hospital, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Allwood","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lowe","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hyde","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bond","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Anderson","sequence":"additional","affiliation":[{"name":"Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,8]]},"reference":[{"key":"key20160826114108453_ref1-bib1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0272-6386(03)00916-8","article-title":"A population-based study of the incidence and outcomes of diagnosed chronic kidney disease","volume":"42","author":"Drey","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"key20160826114108453_ref1-bib2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib3","volume-title":"UK Renal Registry 16th Annual Report: Chapter 2 UK RRT Prevalence in 2012: National and Centre-Specific Analyses","author":"UK Renal Registry (UKRR)","year":"2013"},{"key":"key20160826114108453_ref1-bib4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1001\/jama.294.21.2726","article-title":"Deceased-donor characteristics and the survival benefit of kidney transplantation","volume":"294","author":"Merion","year":"2005","journal-title":"JAMA"},{"key":"key20160826114108453_ref1-bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1681\/ASN.V123589","article-title":"Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates","volume":"12","author":"Ojo","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0971-4065.62086","article-title":"The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians","volume":"20","author":"Bhowmik","year":"2010","journal-title":"Indian J Nephrol"},{"key":"key20160826114108453_ref1-bib7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Medical progress: strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib8","doi-asserted-by":"publisher","first-page":"CD003961","DOI":"10.1002\/14651858.cd003961.pub2","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"4","author":"Webster","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160826114108453_ref1-bib9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/01.TP.0000110408.83054.88","article-title":"Frequency and impact of nonadherence to immunosuppression after renal transplantation: a systematic review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib10","volume-title":"Kidney Disease: Key Facts and Figures","author":"NHS Kidney Care","year":"2010"},{"key":"key20160826114108453_ref1-bib11","volume-title":"Annual Report on Kidney Transplantation Report for 2013\/2014 (1 April 2004 to 31 March 2014)","author":"NHS Blood and Transplant (NHSBT)","year":"2014"},{"key":"key20160826114108453_ref1-bib12","volume-title":"Organ Donation and Transplantation Annual Activity Report 2012\u20132013","author":"NHS Blood and Transplant (NHSBT)"},{"key":"key20160826114108453_ref1-bib13","volume-title":"Organ Donation and Transplantation: Activity Figures for the UK as at 12 April 2013","author":"NHS Blood and Transplant (NHSBT)","year":"2014"},{"key":"key20160826114108453_ref1-bib14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1359105307078172","article-title":"Living with a kidney transplant: a qualitative investigation of quality of life","volume":"12","author":"Orr","year":"2007","journal-title":"J Health Psychol"},{"key":"key20160826114108453_ref1-bib15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/08860220601098862","article-title":"Quality of life in CAPD, transplant, and chronic renal failure patients with diabetes","volume":"29","author":"Apostolou","year":"2007","journal-title":"Ren Fail"},{"key":"key20160826114108453_ref1-bib16","first-page":"521","article-title":"Changes in health-related quality of life in Greek adult patients 1 year after successful renal transplantation","volume":"4","author":"Balaska","year":"2006","journal-title":"Exp Clin Transplant"},{"key":"key20160826114108453_ref1-bib17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0272-6386(89)80053-8","article-title":"Quality of life in end-stage renal-disease: a reexamination","volume":"13","author":"Bremer","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"key20160826114108453_ref1-bib18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1185\/030079908X253410","article-title":"Utility of health states in chronic kidney disease: a structured review of the literature","volume":"24","author":"Dale","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key20160826114108453_ref1-bib19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal-disease","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib20","first-page":"23","article-title":"Transplantation versus dialysis: a study of quality of life","volume":"20","author":"Morris","year":"1988","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5694\/j.1326-5377.1989.tb136562.x","article-title":"Life satisfaction across treatment methods for patients with end-stage renal-failure","volume":"150","author":"Morris","year":"1989","journal-title":"Med J Aust"},{"key":"key20160826114108453_ref1-bib22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.transproceed.2007.03.004","article-title":"Pain affects health-related quality of life in kidney transplant recipients","volume":"39","author":"Nourbala","year":"2007","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib23","first-page":"500","article-title":"Quality-of-life for patients in an end-stage renal-disease program","volume":"71","author":"Seedat","year":"1987","journal-title":"S Afr Med J"},{"key":"key20160826114108453_ref1-bib24","first-page":"7","article-title":"Quality-of-life and rehabilitation differences among 4 end-stage renal-disease therapy groups","volume":"131","author":"Simmons","year":"1990","journal-title":"Scand J Urol Nephrol"},{"key":"key20160826114108453_ref1-bib25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1399-0012.2005.00433.x","article-title":"Quality of life after organ transplantation in type 1 diabetics with end-stage renal disease","volume":"20","author":"Sureshkumar","year":"2006","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib26","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.transproceed.2004.09.019","article-title":"Changes in quality of life after renal transplantation","volume":"37","author":"Overbeck","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib27","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1016\/j.transproceed.2006.08.162","article-title":"The importance of patient satisfaction and health-related quality of life after renal transplantation","volume":"38","author":"Yildirim","year":"2006","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib28","volume-title":"Management of the Failing Kidney Transplant","author":"The British Transplantation Society","year":"2013"},{"key":"key20160826114108453_ref1-bib29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(00)03123-8","article-title":"Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study","volume":"356","author":"Lamping","year":"2000","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1523-1755.2002.00096.x","article-title":"Quality of life in peritoneal dialysis patients: decline over time and association with clinical outcomes","volume":"61","author":"Bakewell","year":"2002","journal-title":"Kidney Int"},{"key":"key20160826114108453_ref1-bib31","first-page":"215","article-title":"Economic evaluation of end stage renal disease treatment","volume":"44","author":"de Wit","year":"1998","journal-title":"NHS Econ Eval Database"},{"key":"key20160826114108453_ref1-bib32","volume-title":"UK Renal Registry 17th Annual Report. Appendix C Renal Services Descried for Non-Physicians","author":"UK Renal Registry (UKRR)","year":"2014"},{"key":"key20160826114108453_ref1-bib33","volume-title":"NHS Standard Contract for Adult Kidney Transplant Service","author":"NHS England","year":"2013"},{"key":"key20160826114108453_ref1-bib34","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"key20160826114108453_ref1-bib35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1053\/j.ajkd.2008.02.308","article-title":"Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review","volume":"51","author":"White","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key20160826114108453_ref1-bib36","volume-title":"The National Service Framework for Renal Services. Part One: Dialysis and Transplantation","author":"Department of Health (DH)","year":"2004"},{"key":"key20160826114108453_ref1-bib37","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/j.1600-6143.2004.00535.x","article-title":"Diminishing significance of HLA matching in kidney transplantation","volume":"4","author":"Su","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib38","doi-asserted-by":"publisher","first-page":"e47915","DOI":"10.1371\/journal.pone.0047915","article-title":"Poor long-term outcome in second kidney transplantation: a delayed event","volume":"7","author":"Trebern-Launay","year":"2012","journal-title":"PLOS ONE"},{"key":"key20160826114108453_ref1-bib39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/TP.0000000000000332","article-title":"Graft and patient survival outcomes of a third kidney transplant","volume":"99","author":"Redfield","year":"2015","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ndt\/gfs269","article-title":"Estimating the financial cost of chronic kidney disease to the NHS in England","volume":"27","author":"Kerr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib41","doi-asserted-by":"publisher","first-page":"C311","DOI":"10.1159\/000328074","article-title":"Renal association clinical practice guideline on post-operative care of the kidney transplant recipient","volume":"118","author":"Baker","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"key20160826114108453_ref1-bib42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/01.tp.0000438205.04348.69","article-title":"The economic burden of posttransplant events in renal transplant recipients in Europe","volume":"97","author":"Chamberlain","year":"2014","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib43","volume-title":"Immunosuppressive Therapy for Renal Transplantation in Adults","author":"National Institute for Health and Care Excellence (NICE)","year":"2004"},{"key":"key20160826114108453_ref1-bib44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semnephrol.2009.10.009","article-title":"Disparities in kidney transplant outcomes: a review","volume":"30","author":"Gordon","year":"2010","journal-title":"Semin Nephrol"},{"key":"key20160826114108453_ref1-bib45","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1046\/j.1523-1755.2000.00287.x","article-title":"Effect of waiting time on renal transplant outcome","volume":"58","author":"Meier-Kriesche","year":"2000","journal-title":"Kidney Int"},{"key":"key20160826114108453_ref1-bib46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1034\/j.1600-6143.3.s4.11.x","article-title":"Expanded criteria donors for kidney transplantation","volume":"3","author":"Metzger","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib47","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1681\/ASN.2005040439","article-title":"Comorbid conditions in kidney transplantation: association with graft and patient survival","volume":"16","author":"Wu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib48","first-page":"299","article-title":"African American (AA) renal transplant recipients (RTR) require higher tacrolimus (TAC) doses to achieve target levels compared to white (W) RTR: does clotrimazole help?","volume":"12","author":"Laftavi","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/00007890-199711150-00008","article-title":"Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients","volume":"64","author":"Neylan","year":"1997","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib50","doi-asserted-by":"publisher","first-page":"S237A","DOI":"10.1097\/00007890-199904150-00948","article-title":"Effect of race on efficacy and safety of sirolimus vs. azathioprine\u2009+\u2009standard immunotherapy in renal transplantation","volume":"67","author":"Neylan","year":"1999","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib51","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the SYMPHONY pharmacokinetic substudy","volume":"24","author":"Grinyo","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib52","volume-title":"Kidney Transplant Protocol","author":"Nottingham University Hospitals NHS Trust","year":"2013"},{"key":"key20160826114108453_ref1-bib53","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/j.1600-6143.2008.02373.x","article-title":"Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation","volume":"8","author":"Muthusamya","year":"2008","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib54","volume-title":"EdRen Handbook: Renal Transplant Protocols","author":"Royal Infirmary of Edinburgh","year":"2007"},{"key":"key20160826114108453_ref1-bib55","volume-title":"Commercial Medicines Unit"},{"key":"key20160826114108453_ref1-bib56","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014","edition":"68th edn."},{"key":"key20160826114108453_ref1-bib57","volume-title":"Drug Tariff","author":"NHS Business Services Authority"},{"key":"key20160826114108453_ref1-bib58","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1399-0012.2009.01162.x","article-title":"Tacrolimus combined with two different corticosteroid-free regimens compared with a standard triple regimen in renal transplantation: 1 year observational results","volume":"24","author":"Kr\u00e4mer","year":"2010","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib60","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/TP.0b013e3181ff87cd","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib61","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib62","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/ajt.12460","article-title":"Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study","volume":"13","author":"Rostaing","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib63","volume-title":"Immunosuppressive Therapy for Kidney Transplantation in Adults (Review of Technology Appraisal Guidance 85). Belatacept Submission of Evidence","author":"Bristol-Myers Squibb","year":"2014"},{"key":"key20160826114108453_ref1-bib64","volume-title":"NHS Reference Costs 2013 to 2014","author":"Department of Health (DH)","year":"2014"},{"issue":"21","key":"key20160826114108453_ref1-bib65","doi-asserted-by":"publisher","DOI":"10.3310\/hta9210","article-title":"Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study","volume":"9","author":"Woodroffe","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20160826114108453_ref1-bib66","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Healthcare","author":"NHS Centre for Reviews and Dissemination (CRD)","year":"2009"},{"issue":"49","key":"key20160826114108453_ref1-bib67","doi-asserted-by":"publisher","DOI":"10.3310\/hta10490","article-title":"A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children","volume":"10","author":"Yao","year":"2006","journal-title":"Health Technol Assess"},{"key":"key20160826114108453_ref1-bib68","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key20160826114108453_ref1-bib69","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key20160826114108453_ref1-bib70","volume-title":"NICE DSU Technical Support Document 7: Evidence Synthesis of Treatment Efficacy in Decision making: A Reviewer\u2019s Checklist","author":"Ades","year":"2012"},{"key":"key20160826114108453_ref1-bib71","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib73","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/00007890-200110150-00014","article-title":"A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients","volume":"72","author":"Ponticelli","year":"2001","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00007890-200301150-00007","article-title":"Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation","volume":"75","author":"Lawen","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib75","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.V131213","article-title":"Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression","volume":"13","author":"Van Duijnhoven","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib76","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0041-1345(02)03033-6","article-title":"Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy","volume":"34","author":"Waller","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib78","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0041-1345(02)02861-0","article-title":"Mycophenolate mofetil in renal transplantation: five years experience","volume":"34","author":"Tuncer","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib79","first-page":"86","article-title":"FK 506 versus cyclosporin in the prevention of renal allograft rejection: European pilot study six-week results","volume":"8","author":"Schleibner","year":"1995","journal-title":"Transplant Int"},{"key":"key20160826114108453_ref1-bib80","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1432-2277.1998.tb00948.x","article-title":"Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506","volume":"11","author":"Radermacher","year":"1998","journal-title":"Transplant Int"},{"key":"key20160826114108453_ref1-bib82","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1046\/j.1523-1755.2002.00149.x","article-title":"Molecular and structural consequences of early renal allograft injury","volume":"61","author":"Baboolal","year":"2002","journal-title":"Kidney Int"},{"key":"key20160826114108453_ref1-bib83","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/S0041-1345(02)02968-8","article-title":"One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation","volume":"34","author":"Campos","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib84","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study","volume":"359","author":"Margreiter","year":"2002","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib85","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.transproceed.2003.11.056","article-title":"Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies","volume":"36","author":"T\u00f6z","year":"2004","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib86","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00007890-200208270-00013","article-title":"Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study","volume":"74","author":"Sadek","year":"2002","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib87","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib88","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib89","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation","volume":"61","author":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","year":"1996","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib90","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0041-1345(98)01929-0","article-title":"Tacrolimus\/\u2018low-dose\u2019 mycophenolate mofetil versus microemulsion cyclosporine\/\u2018low-dose\u2019 mycophenolate mofetil after kidney transplantation: 1-year follow-up of a prospective, randomized clinical trial","volume":"31","author":"Yang","year":"1999","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib91","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.transproceed.2013.01.060","article-title":"Comparison of cyclosporine and sirolimus effects on serum creatinine level over five years after kidney transplantation","volume":"45","author":"Soleimani","year":"2013","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib92","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib93","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/TP.0b013e3181613e65","article-title":"Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation","volume":"85","author":"Smith","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib94","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study","volume":"6","author":"V\u00edtko","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib95","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0041-1345(02)03769-7","article-title":"Randomised trial of simulect versus placebo for control of acute rejection in renal allograft recipients","volume":"35","author":"Bingyi","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib96","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1016\/S0041-1345(01)02435-6","article-title":"Induction versus noninduction protocols in anti-calcineurin-based immunosuppression","volume":"33","author":"Charpentier","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib97","first-page":"393","article-title":"Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial","volume":"16","author":"Sheashaa","year":"2003","journal-title":"J Nephrol"},{"key":"key20160826114108453_ref1-bib98","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00007890-200407271-01219","article-title":"Assessment of two strategies of neoral\u00ae administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic\u00ae, steroids and anti-il2r antibodies: 6 months interim results","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1432-2277.2004.00055.x","article-title":"Long-term results of a prospective randomized trial comparing tacrolimus versus cyclosporine in African-American recipients of primary cadaver renal transplant","volume":"18","author":"Jarzembowski","year":"2005","journal-title":"Transplant Int"},{"key":"key20160826114108453_ref1-bib100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.TP.0000162980.68628.5A","article-title":"A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients","volume":"80","author":"Hardinger","year":"2005","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib101","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1681\/ASN.2006101153","article-title":"Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial","volume":"18","author":"Remuzzi","year":"2007","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib102","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5507\/bp.2012.008","article-title":"In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized 1 year study comparing cyclosporine A and tacrolimus based regiments","volume":"156","author":"Zadrazil","year":"2012","journal-title":"Biomed Papo Med Fac Univ Palack\u00fd"},{"key":"key20160826114108453_ref1-bib103","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1681\/ASN.2005030249","article-title":"No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at 1 year","volume":"17","author":"Rowshani","year":"2006","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib104","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/j.1600-6143.2006.01407.x","article-title":"Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens","volume":"6","author":"Weimer","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib105","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3349\/ymj.2014.55.5.1341","article-title":"Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation","volume":"55","author":"Oh","year":"2014","journal-title":"Yonsei Med J"},{"key":"key20160826114108453_ref1-bib106","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/TP.0b013e3181734b4a","article-title":"Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab\/thymoglobulin: 1 year follow-up","volume":"86","author":"Ciancio","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib107","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib108","first-page":"649","article-title":"The Cairo Kidney Center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes","volume":"5","author":"Barsoum","year":"2007","journal-title":"Exp Clin Transplant"},{"key":"key20160826114108453_ref1-bib109","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/01.ASN.0000102469.32182.8C","article-title":"Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function","volume":"15","author":"Stallone","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib110","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/01.tp.0000173378.28790.0b","article-title":"Comparison of steroid avoidance in tacrolimus\/mycophenolate mofetil and tacrolimus\/sirolimus combination in kidney transplantation monitored by surveillance biopsy","volume":"80","author":"Anil Kumar","year":"2005","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib111","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","article-title":"Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen","volume":"22","author":"Sampaio","year":"2008","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib113","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1097\/01.tp.0000232688.76018.19","article-title":"High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation","volume":"82","author":"Gelens","year":"2006","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib114","doi-asserted-by":"publisher","first-page":"731426","DOI":"10.1155\/2010\/731426","article-title":"Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: results of a randomized multicenter trial in renal transplantation","author":"Van Gurp","year":"2010","journal-title":"J Transplant"},{"key":"key20160826114108453_ref1-bib115","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib116","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib117","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib118","first-page":"300","article-title":"Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up","volume":"6","author":"Nafar","year":"2012","journal-title":"Iran J Kidney Dis"},{"key":"key20160826114108453_ref1-bib119","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1111\/ajt.12481","article-title":"Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients","volume":"13","author":"Silva","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib120","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1111\/j.1600-6143.2005.01064.x","article-title":"Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation","volume":"5","author":"Hamdy","year":"2005","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib121","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0929-6646(08)60166-7","article-title":"Favorable results of concomitant tacrolimus and sirolimus therapy in Taiwanese renal transplant recipients at 12 months","volume":"107","author":"Chen","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"key20160826114108453_ref1-bib122","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes","volume":"20","author":"Anil Kumar","year":"2008","journal-title":"Transpl Immunol"},{"key":"key20160826114108453_ref1-bib123","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib124","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib125","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1056\/NEJM200511103531919","article-title":"Costimulation blockade with belatacept in renal transplantation: reply","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib127","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporin","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib128","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyll\u00f6nen","year":"2007","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib129","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/TP.0b013e31824215b7","article-title":"A randomized trial with steroids and antithymocyte globulins comparing cyclosporine\/azathioprine versus tacrolimus\/mycophenolate mofetil (CATM2) in renal transplantation","volume":"93","author":"Vacher-Coponat","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib130","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/01.tp.0000282872.17024.b7","article-title":"Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression","volume":"84","author":"Hern\u00e1ndez","year":"2007","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"key20160826114108453_ref1-bib132","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib133","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib134","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib135","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","article-title":"Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal","volume":"92","author":"Heilman","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib136","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0041-1345(03)00213-6","article-title":"Bic\u00eatre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study","volume":"35","author":"Charpentier","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib137","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib138","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1600-6143.2004.00533.x","article-title":"Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil","volume":"4","author":"Merville","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib139","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1432-2277.2004.00011.x","article-title":"Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens","volume":"18","author":"Wlodarczyk","year":"2005","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib140","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/j.1600-6143.2009.02794.x","article-title":"Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial","volume":"9","author":"Wlodarczyk","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib141","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/TP.0b013e318296c9d5","article-title":"Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus","volume":"96","author":"Tsuchiya","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib142","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib143","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib144","doi-asserted-by":"publisher","first-page":"613","DOI":"10.5301\/JN.2011.6247","article-title":"Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients","volume":"24","author":"Bertoni","year":"2011","journal-title":"J Nephrol"},{"key":"key20160826114108453_ref1-bib145","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/j.1600-6143.2006.01340.x","article-title":"Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF","volume":"6","author":"Gallon","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib146","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/TP.0b013e318160d3c9","article-title":"Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor","volume":"85","author":"Durrbach","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib147","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib148","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib149","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib150","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1097\/01.tp.0000188300.26762.74","article-title":"Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus\/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the atlas study","volume":"80","author":"V\u00edtko","year":"2005","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib151","first-page":"82","article-title":"4-year results from the long-term extension of the belatacept BENEFIT study","volume":"12","author":"Larsen","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib152","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib153","doi-asserted-by":"publisher","first-page":"114","DOI":"10.7182\/prtr.1.9.2.t4l566l63m0g1126","article-title":"New strategies using \u2018low-dose\u2019 mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation","volume":"9","author":"Ulsh","year":"1999","journal-title":"J Transpl Coord"},{"key":"key20160826114108453_ref1-bib154","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib155","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib156","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1681\/ASN.2009111109","article-title":"Five-year safety and efficacy of belatacept in renal transplantation","volume":"21","author":"Vincenti","year":"2010","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib157","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/TP.0b013e3182394cb3","article-title":"Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal","volume":"93","author":"Heilman","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib158","first-page":"32","article-title":"Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients \u2013 long term results","volume":"13","author":"Samsel","year":"2008","journal-title":"Ann Transplant"},{"key":"key20160826114108453_ref1-bib159","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/00007890-200112270-00008","article-title":"Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection","volume":"72","author":"Sollinger","year":"2001","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib160","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11255-007-9242-6","article-title":"Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation","volume":"40","author":"Sheashaa","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"key20160826114108453_ref1-bib161","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/00007890-199606150-00005","article-title":"One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group","volume":"61","author":"Vincenti","year":"1996","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib162","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0041-1345(99)00789-7","article-title":"Four-year follow-up of the European Tacrolimus Multicenter Renal Study","volume":"31","author":"Mayer","year":"1999","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib163","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0041-1345(02)02942-1","article-title":"Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study","volume":"34","author":"Mayer","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib164","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results","volume":"20","author":"Kr\u00e4mer","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib165","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1093\/ndt\/gfn004","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results","volume":"23","author":"Kr\u00e4mer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib166","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/bjs.4134","article-title":"Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis","volume":"90","author":"Murphy","year":"2003","journal-title":"Br J Surg"},{"key":"key20160826114108453_ref1-bib167","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib168","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","article-title":"A blinded, long-term, randomized multicentre study of mycophenolate mofetil in cadaveric renal transplantation: results at three years","volume":"65","author":"Mathew","year":"1998","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib169","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/TP.0b013e31825475a3","article-title":"Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial","volume":"94","author":"Clayton","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib170","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0140-6736(04)16808-6","article-title":"Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial","volume":"364","author":"Remuzzi","year":"2004","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib171","first-page":"28","article-title":"Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients","volume":"7","author":"Wlodarczyk","year":"2002","journal-title":"Ann Transplant"},{"key":"key20160826114108453_ref1-bib172","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.transproceed.2005.02.088","article-title":"sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil","volume":"37","author":"Weimer","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib173","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/TP.0b013e3182003d76","article-title":"Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis","volume":"91","author":"Ciancio","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib174","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib175","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/ajt.12459","article-title":"Long-term exposure to belatacept in recipients of extended criteria donor kidneys","volume":"13","author":"Charpentier","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib176","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"V\u00edtko","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib177","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"V\u00edtko","year":"2005","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib178","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":"Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study","volume":"12","author":"Budde","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib179","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib180","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib181","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2215\/CJN.06940711","article-title":"Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus\/mycophenolate mofetil versus tacrolimus\/sirolimus","volume":"7","author":"Chhabra","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib182","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib183","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib184","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib185","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1111\/j.1600-6143.2009.02803.x","article-title":"Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus","volume":"9","author":"Servais","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib186","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1600-6143.2011.03637.x","article-title":"Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the postconcept study","volume":"11","author":"Lebranchu","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib187","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1111\/j.1600-6143.2011.03697.x","article-title":"Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine","volume":"11","author":"Joannid\u00e8s","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib188","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/j.1600-6143.2012.04036.x","article-title":"Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the spiesser study","volume":"12","author":"Lebranchu","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib189","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1432-2277.2010.01122.x","article-title":"Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients","volume":"23","author":"Joannides","year":"2010","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib190","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1432-2277.2005.00163.x","article-title":"Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus","volume":"18","author":"Campistol","year":"2005","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib191","doi-asserted-by":"publisher","first-page":"S125\u20137","DOI":"10.1016\/S0041-1345(03)00226-4","article-title":"Kidney transplantation without calcineurin inhibitors using sirolimus","volume":"35","author":"Stegall","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib192","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1681\/ASN.2007091001","article-title":"Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients","volume":"19","author":"Hamdy","year":"2008","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib193","first-page":"283","article-title":"Proteinuria among primarily sirolimus treated live-donor renal transplant recipients\u2019 long-term experience","volume":"8","author":"Hamdy","year":"2010","journal-title":"Exp Clin Transplant"},{"key":"key20160826114108453_ref1-bib194","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib195","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib196","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","article-title":"Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study","volume":"25","author":"Ekberg","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib197","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1432-2277.2009.00937.x","article-title":"Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study","volume":"22","author":"Demirbas","year":"2009","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib198","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1399-0012.2009.01093.x","article-title":"Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study","volume":"24","author":"Frei","year":"2010","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib199","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib200","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/01.tp.0000203558.34739.c6","article-title":"Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years","volume":"81","author":"Kumar","year":"2006","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib201","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Cochrane","year":"2008"},{"key":"key20160826114108453_ref1-bib202","first-page":"69","article-title":"Mycophenolate vs. azathioprine for kidney transplantation: 15 year follow-up of a randomized trial","volume":"16","author":"Clayton","year":"2011","journal-title":"Nephrology"},{"key":"key20160826114108453_ref1-bib203","first-page":"200","article-title":"Tacrolimus preserves renal function better than cyclosporin at 10 years: long term results of a randomised controlled trial","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib204","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","article-title":"Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study","volume":"10","author":"Kr\u00e4mer","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib205","volume":"3","author":"Kr\u00e4mer","year":"2010","journal-title":"NDT Plus"},{"key":"key20160826114108453_ref1-bib206","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib207","doi-asserted-by":"publisher","first-page":"iii262","DOI":"10.1097\/00007890-201007272-00303","article-title":"Belatacept vs. cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study","volume":"3","author":"Durrbach","year":"2010","journal-title":"NDT Plus"},{"key":"key20160826114108453_ref1-bib208","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/01.TP.0000057240.95073.35","article-title":"Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients","volume":"75","author":"Stallone","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib209","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1111\/j.1600-6143.2005.01123.x","article-title":"Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression","volume":"5","author":"Flechner","year":"2005","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib210","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-9610(99)00042-2","article-title":"A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants","volume":"177","author":"Raofi","year":"1999","journal-title":"Am J Surg"},{"key":"key20160826114108453_ref1-bib211","volume-title":"NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision making","author":"Dias","year":"2011"},{"key":"key20160826114108453_ref1-bib212","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib213","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/j.1600-6143.2012.04174.x","article-title":"A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients","volume":"12","author":"Alloway","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib214","doi-asserted-by":"publisher","first-page":"E685","DOI":"10.1111\/ctr.12256","article-title":"A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients","volume":"27","author":"Bloom","year":"2013","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib215","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/TP.0b013e318256dd13","article-title":"Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure","volume":"93","author":"Connor","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib216","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/ckj\/sfs154","article-title":"A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport or Prograf preparations of tacrolimus","volume":"6","author":"Connor","year":"2013","journal-title":"Clin Kidney J"},{"key":"key20160826114108453_ref1-bib217","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2146\/ajhp120783","article-title":"Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients","volume":"70","author":"Heavner","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"key20160826114108453_ref1-bib218","first-page":"484","article-title":"Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study","volume":"38","author":"Marfo","year":"2013","journal-title":"P&T"},{"key":"key20160826114108453_ref1-bib219","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/TP.0b013e31822a79ad","article-title":"A multicenter experience with generic tacrolimus conversion","volume":"92","author":"McDevitt-Potter","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib220","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/TP.0000000000000149","article-title":"Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients","volume":"97","author":"Richards","year":"2014","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib221","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ckj\/sfu015","article-title":"Systematic conversion to generic tacrolimus in stable kidney transplant recipients","volume":"7","author":"Rosenborg","year":"2014","journal-title":"Clin Kidney J"},{"key":"key20160826114108453_ref1-bib222","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/phar.1130","article-title":"Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system","volume":"32","author":"Spence","year":"2012","journal-title":"Pharmacotherapy"},{"key":"key20160826114108453_ref1-bib223","unstructured":"Babu A, Ravanan R, Udayara. Adoport-v-Prograf in De-Novo Renal Transplants: Single Centre Experience. Joint Congress of the British Transplantation Society & Renal Association. Bournemouth, UK, March 2013."},{"key":"key20160826114108453_ref1-bib224","unstructured":"Betmouni R, Bedi R, Duncan N, Galliford J, Goodall D, Owen J, et al. Switching Prograf\u00ae to generic tacrolimus (Adoport\u00ae) is safe and cost effective in renal and pancreas transplants. Joint Congress of the British Transplantation Society and Renal Association, Glasgow, UK, February 2012."},{"key":"key20160826114108453_ref1-bib225","first-page":"148","article-title":"Pharmacist-managed conversion of Prograf to generic tacrolimus in kidney and liver transplant patients with stable allograft function","volume":"7","author":"Chiu","year":"2012","journal-title":"Hawaii J Med Public Health"},{"key":"key20160826114108453_ref1-bib226","first-page":"203","article-title":"Conversion of Prograf\u00ae to generic tacrolimus in stable renal transplant recipients","volume":"12","author":"Crowther","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib227","first-page":"354","article-title":"Comparison of dose requirements of Sandoz\u2122 generic tacrolimus with brand Prograf\u00ae in kidney transplant recipients","volume":"11","author":"Dick","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib228","first-page":"240","article-title":"Extended comparison of therapeutic treatment outcomes of de novo liver and kidney transplant recipients with generic tacrolimus (Sandoz\u2122 or Brand Name (Prograf\u00ae)","volume":"12","author":"Heldenbrand","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib229","first-page":"226","article-title":"Generic switch of tacrolimus in prevalent kidney transplant recipients","volume":"13","author":"Jogia","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib230","unstructured":"Kendrew P, Edey M, Bhandan S. An Investigation into the Differences Between Adoport\u00ae and Prograf\u00ae in Kidney Transplant Recipients. Joint Congress of the British Transplantation Society and Renal Association, Bournemouth, UK, March 2013."},{"key":"key20160826114108453_ref1-bib231","first-page":"205","article-title":"Effect of generic tacrolimus on the incidence of acute rejection in kidney transplant recipients: a single center experience","volume":"12","author":"Qazi","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib232","unstructured":"Sharma H, El-Bakry A, Wong C. Assessment of Post Transplantation Results of Adoport Compared to Prograf: A Short Sample Study. Joint Congress of the British Transplantation Society and Renal Association, Bournemouth, UK, March 2013."},{"key":"key20160826114108453_ref1-bib233","unstructured":"Shiu K, Rezk T, Henry J. Programmed Switching of Renal Transplant Recipients from Branded to Generic Tacrolimus is Safe, Well-Tolerated and Cost-Effective. Joint Congress of the British Transplantation Society and Renal Association, Bournemouth, UK, March 2013."},{"key":"key20160826114108453_ref1-bib234","first-page":"242","article-title":"Clinical and economic outcomes: de novo use of FDA-approved bioequivalent formulation of generic tacrolimus versus brand tacrolimus (Prograf)","volume":"11","author":"Siddiqi","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib235","first-page":"82","article-title":"Tacrolimus dosing in renal transplant recipients following introduction of a generic preparation","volume":"26","author":"Storey","year":"2013","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib236","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00007890-201211271-01465","article-title":"The effect of generic substitution of tacrolimus in liver and kidney transplant recipients","volume":"94","author":"Venkataramanan","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib237","first-page":"72","article-title":"Switching branded immunosuppressants in a stable renal transplant population: a single centre experience","volume":"21","author":"Wilcock","year":"2013","journal-title":"Int J Pharm Pract"},{"key":"key20160826114108453_ref1-bib238","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4236\/ojneph.2012.24012","article-title":"How safe is conversion from tacrolimus to its generic drug? A single center experience. Open","volume":"2","author":"Marsen","year":"2012","journal-title":"J Nephrol"},{"key":"key20160826114108453_ref1-bib239","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib240","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"key20160826114108453_ref1-bib241","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.transproceed.2003.09.036","article-title":"Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients","volume":"35","author":"Abou-Jaoude","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib242","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.transproceed.2005.08.040","article-title":"Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients","volume":"37","author":"Abou-Jaoude","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib243","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S0041-1345(00)02471-4","article-title":"Canadian multicentre trial of tacrolimus\/azathioprine\/steroids versus tacrolimus\/mycophenolate mofetil\/steroids versus neoral\/mycophenolate mofetil\/steroids in renal transplantation","volume":"33","author":"Busque","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib244","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00007890-200003150-00028","article-title":"Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation","volume":"69","author":"Johnson","year":"2000","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib245","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/S0041-1345(03)00576-1","article-title":"Tacrolimus-basiliximab versus cyclosporine-basiliximab in renal transplantation \u2018de novo\u2019: acute rejection and complications","volume":"35","author":"Garcia","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib246","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0041-1345(98)00248-6","article-title":"Prospective randomized study comparing FK 506 (Prograf) and cyclosporine a (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases","volume":"30","author":"Morris-Stiff","year":"1998","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib247","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib248","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S0041-1345(00)01408-1","article-title":"Tacrolimus vs. CyA neoral in combination with MMF and steroids after cadaveric renal transplantation","volume":"32","author":"Wang","year":"2000","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib249","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0041-1345(00)00910-6","article-title":"Randomized trial comparing neoral and tacrolimus immunosuppression for recipients of renal transplants procured from different donor groups","volume":"32","author":"White","year":"2000","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib250","first-page":"008","article-title":"A randomised trial comparing Neoral (ciclosporin) and tacrolimus immunosuppression for recipients of renal transplants procured from different donor groups","volume":"86","author":"Williams","year":"1998","journal-title":"Br J Surg"},{"key":"key20160826114108453_ref1-bib251","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib252","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1111\/ajt.12437","article-title":"Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen","volume":"13","author":"Chhabra","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib253","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib254","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at 1 year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib255","first-page":"1131","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. 1. Drug interactions and rejection at 1 year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib256","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib257","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib258","first-page":"42","article-title":"Extended-release tacrolimus plus everolimus or micophenolate mofetil in deceased donor kidney transplant recipients: 6-month results of a prospective randomized clinical trial","volume":"12","author":"Favi","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib259","first-page":"112","article-title":"Better renal function with early everolimus (EVL) introduction and calcineurin inhibitor (CNI) withdrawal at third month in kidney recipients at month 12: results of the ERIC study","volume":"24","author":"Ruiz","year":"2011","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib260","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0161-5890(03)00070-1","article-title":"Tacrolimus (FK506) versus cyclosporin A microemulsion (Neoral) maintenance immunosuppression: effects on graft survival and function, infection, and metabolic profile following kidney transplantation (KT)","volume":"39","author":"Abou-Jaoude","year":"2003","journal-title":"Mol Immunol"},{"key":"key20160826114108453_ref1-bib261","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1432-2277.2006.00335.x","article-title":"Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients","volume":"19","author":"Cheung","year":"2006","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib262","unstructured":"Egfjord M, Ladefoged J, Olgaard K. Similar Frequency of Acute Rejection, Graft-and Patient Survival in Quadruple Therapy with Tacrolimus Versus Cyclosporin in Combination with Prednisone, Mycophenolate Mofetil, and ATGAM after Renal Allotransplantation. XIXth International Congress of the Transplantation Society, Miami, FL, 25\u201330 August 2002."},{"key":"key20160826114108453_ref1-bib263","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0041-1345(02)03094-4","article-title":"One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine","volume":"34","author":"El Haggan","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib264","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0041-1345(02)04003-4","article-title":"Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function","volume":"35","author":"Liu","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib265","unstructured":"Tsinalis D, Binet I, Dickenmann M, Steiger J, Brunner F, Thiel G. Cost of Medical Care after Renal Transplantation Comparing Cyclosporine-Mycophenolate to Tacrolimus-Azathioprine: A Randomised Controlled Study. XVIII International Congress of the Transplantation Society, Rome, August\/September 2000."},{"key":"key20160826114108453_ref1-bib266","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0041-1345(00)01405-6","article-title":"Clinical experience with prograf (Tacrolimus, FK 506) in Chinese patients after renal transplantation","volume":"32","author":"Yu","year":"2000","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib267","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/S0041-1345(02)03530-3","article-title":"Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-neoral","volume":"34","author":"Nichelle","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib268","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1399-0012.1998.tb00998.x","article-title":"Distal tubular acidosis induced by FK506","volume":"12","author":"Heering","year":"1998","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib269","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"key":"key20160826114108453_ref1-bib270","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1016\/S0041-1345(01)02379-X","article-title":"Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients","volume":"33","author":"Salvadori","year":"2001","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib271","first-page":"112","article-title":"Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients","volume":"66","author":"Salvadori","year":"2006","journal-title":"Clin Nephrol"},{"key":"key20160826114108453_ref1-bib272","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","article-title":"Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study","volume":"4","author":"Budde","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib273","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.transproceed.2004.12.048","article-title":"Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study","volume":"37","author":"Budde","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib274","first-page":"454","article-title":"Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)","volume":"35","author":"Budde","year":"2006","journal-title":"Nieren Hochdruck"},{"key":"key20160826114108453_ref1-bib275","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1432-2277.2009.00877.x","article-title":"Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation","volume":"22","author":"Shehata","year":"2009","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib276","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/TP.0b013e31822527ca","article-title":"Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium","volume":"92","author":"Ortega","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib277","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-0012.2012.01694.x","article-title":"Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry","volume":"27","author":"Langone","year":"2013","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib278","first-page":"337","article-title":"Mycophenolic acid (MPA) dosing: effect on efficacy to 4 years after kidney transplantation in the mycophenolic acid observational renal transplant (MORE) study","volume":"13","author":"Chan","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib279","first-page":"1","article-title":"Drug tolerability and outcomes in kidney transplant recipients treated with two formulations of mycophenolic acid","volume":"1","author":"Shah","year":"2013","journal-title":"J Pharma Drug Develop"},{"key":"key20160826114108453_ref1-bib280","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/tp.0b013e318205568c","article-title":"Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study","volume":"91","author":"Langone","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib281","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/01.tp.0000209411.66790.b3","article-title":"Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium","volume":"81","author":"Chan","year":"2006","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib282","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3346\/jkms.2010.25.12.1759","article-title":"Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus","volume":"25","author":"Hwang","year":"2010","journal-title":"J Korean Med Sci"},{"key":"key20160826114108453_ref1-bib283","first-page":"509","article-title":"Everolimus-treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib284","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib285","first-page":"300","article-title":"Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de-novo renal transplant patients: 12 month results","volume":"12","author":"Takahara","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib286","first-page":"314","article-title":"Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24-month, randomized, multicenter study","volume":"13","author":"Saito","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib287","first-page":"31","article-title":"Everolimus for regression of left ventricular hypertrophy of renal transplant recipients: a randomized controlled trial","volume":"12","author":"Paoletti","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib288","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","article-title":"Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial","volume":"93","author":"Paoletti","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib289","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.transproceed.2009.03.019","article-title":"Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up","volume":"41","author":"Favi","year":"2009","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib290","first-page":"241","article-title":"A prospective clinical trial comparing tacrolimus-MMF to cyclosporine-everolimus in de novo renal transplant recipients: 2 years results","volume":"22","author":"Favi","year":"2009","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib291","first-page":"506","article-title":"The combination of everolimus and low dose cyclosporine allows similar results as the standard tacrolimus and MMF regimen: 3 year results of a prospective clinical trial in renal transplant recipients","volume":"10","author":"Favi","year":"2010","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib292","first-page":"426","article-title":"Thymoglobulin plus basiliximab vs. basiliximab as induction therapy in deceased donor kidney transplant recipients treated with tacrolimus and mycophenolate mofetil: 1-year results of a prospective clinical trial","volume":"13","author":"Favi","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib293","first-page":"140","article-title":"Everolimus versus azathioprine in a cyclosporine and ketoconazole based immunosuppressive therapy in kidney transplantation: 1-year follow-up of a comparative clinical trial","volume":"20","author":"Gonzalez","year":"2007","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib294","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/01.tp.0000331145.10647.c0","article-title":"Efficacy and safety of everolimus with low dose cyclosporine A compared with mycophenolate mofetil and full dose cyclosporine A in de novo renal transplant recipients","volume":"86","author":"Miserlis","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib295","first-page":"197","article-title":"Efficacy and safety of everolimus based immunosuppression on de novo kidney transplantation with 4 years follow-up, especially in protocol biopsy findings and donor specific antibody production","volume":"26","author":"Watarai","year":"2013","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib296","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.transproceed.2010.03.120","article-title":"De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis","volume":"42","author":"Loriga","year":"2010","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib297","first-page":"380","article-title":"Everolimus (certican\u2122, RAD) is associated with a reduced incidence of CMV infection following renal transplantation","volume":"2","author":"Dantal","year":"2002","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib298","first-page":"459","article-title":"36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients","volume":"3","author":"Oppenheimer","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib299","volume-title":"RAD001\/Everolimus: A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing the Safety and Efficacy of Concentration-controlled Everolimus with Low dose Tacrolimus to CellCept (Mycophenolate Mofetil) with Standard Dose Tacrolimus in de novo Renal Transplant Recipients","author":"Novartis","year":"2014"},{"key":"key20160826114108453_ref1-bib300","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00007890-201211271-00006","article-title":"A prospective randomized trial aimed to reduce the incidence of cytomegalovirus (CMV) infection in kidney transplant recipients","volume":"94","author":"Tedesco","year":"2012","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib301","first-page":"56","article-title":"A prospective randomized trial aimed to reduce the incidence of cytomegalovirus (CMV) infection in kidney transplant (KT) recipients","volume":"13","author":"Tedesco","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib302","first-page":"316","article-title":"Extended-release tacrolimus plus everolimus vs. extended-release tacrolimus plus micophenolate mofetil in primary deceased donor kidney transplant recipients: 1-year results of an open label, randomized phase 2 clinical trial","volume":"13","author":"Favi","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib303","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5414\/CNP63080","article-title":"Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus","volume":"63","author":"Kamar","year":"2005","journal-title":"Clin Nephrol"},{"key":"key20160826114108453_ref1-bib304","first-page":"A4785","article-title":"Assessment of renal function in de novo renal transplant patients receiving either sirolimus or everolimus in addition to cyclosporine A","volume":"12","author":"Rostaing","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib305","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria","volume":"21","author":"Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"key20160826114108453_ref1-bib306","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10198-009-0148-3","article-title":"Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach","volume":"11","author":"J\u00fcrgensen","year":"2010","journal-title":"Eur J Health Econ"},{"key":"key20160826114108453_ref1-bib307","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10198-014-0579-3","article-title":"Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany","volume":"16","author":"J\u00fcrgensen","year":"2015","journal-title":"Eur J Health Econ"},{"key":"key20160826114108453_ref1-bib308","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1681\/ASN.2007040495","article-title":"Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation","volume":"19","author":"Earnshaw","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib309","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2165\/00019053-200321170-00003","article-title":"The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes","volume":"21","author":"Orme","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"key20160826114108453_ref1-bib310","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.clinthera.2005.11.002","article-title":"Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom","volume":"27","author":"McEwan","year":"2005","journal-title":"Clin Ther"},{"key":"key20160826114108453_ref1-bib311","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00019053-200624010-00006","article-title":"Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK","volume":"24","author":"McEwan","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"key20160826114108453_ref1-bib312","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1592\/phco.23.4.443.32119","article-title":"Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients","volume":"23","author":"Crompton","year":"2003","journal-title":"Pharmacotherapy"},{"key":"key20160826114108453_ref1-bib313","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S0041-1345(03)00378-6","article-title":"Cost-effectiveness analysis of basixilimab induction and calcineurin-sparing protocols in \u2018old to old\u2019 programs using Markov models","volume":"35","author":"Emparan","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib314","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1586\/1744666X.2.2.183","article-title":"Economic evaluation of new immunosuppressive drugs in renal transplantation","volume":"2","author":"Emparan","year":"2006","journal-title":"Expert Rev Clin Immunol"},{"key":"key20160826114108453_ref1-bib315","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1432-2277.2002.tb00204.x","article-title":"The economics of renal transplantation with basiliximab (simulect) in preventing acute rejection in renal transplantation","volume":"15","author":"Chilcott","year":"2002","journal-title":"Transplant Int"},{"key":"key20160826114108453_ref1-bib316","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2165\/00019053-200321020-00005","article-title":"Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective","volume":"21","author":"Walters","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"key20160826114108453_ref1-bib317","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/01.tp.0000442505.10490.20","article-title":"Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants","volume":"97","author":"Popat","year":"2014","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib318","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2147\/PPA.S69461","article-title":"Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales","volume":"8","author":"Muduma","year":"2014","journal-title":"Patient Prefer Adher"},{"key":"key20160826114108453_ref1-bib319","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0041-1345(02)02964-0","article-title":"A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation","volume":"34","author":"Craig","year":"2002","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib320","first-page":"580","article-title":"Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses","volume":"15","author":"Lazzaro","year":"2002","journal-title":"J Nephrol"},{"key":"key20160826114108453_ref1-bib321","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.transproceed.2008.03.090","article-title":"Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis","volume":"40","author":"Abecassis","year":"2008","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib322","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"36","key":"key20160826114108453_ref1-bib323","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20160826114108453_ref1-bib324","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3111\/13696998.2014.916713","article-title":"A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability","volume":"17","author":"Muduma","year":"2014","journal-title":"J Med Econ"},{"key":"key20160826114108453_ref1-bib325","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/PPA.S60213","article-title":"Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence","volume":"8","author":"Muduma","year":"2014","journal-title":"Patient Prefer Adher"},{"key":"key20160826114108453_ref1-bib326","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib327","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/ndt\/gfg1028","article-title":"Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation","volume":"18","author":"Jurewicz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib328","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1987"},{"key":"key20160826114108453_ref1-bib329","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1592\/phco.23.4.443.32119","article-title":"Economic analysis of basiliximab and mycophenolate mofetil in living-related donor renal transplant program","volume":"23","author":"Crompton","year":"2003","journal-title":"Pharmacotherapy"},{"key":"key20160826114108453_ref1-bib330","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.transproceed.2005.03.008","article-title":"The cost-effectiveness of basiliximab induction in \u2018old-to-old\u2019 kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis","volume":"37","author":"Emparan","year":"2005","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib331","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0041-1345(03)00379-8","article-title":"Calcineurin-free protocols with basiliximab induction allow patients included in \u2018old to old\u2019 programs achieve standard kidney transplant function","volume":"35","author":"Emparan","year":"2003","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib332","volume-title":"An Introduction to Numerical Analysis","author":"Atkinson, Kendall E","year":"1989","edition":"2nd edn."},{"key":"key20160826114108453_ref1-bib333","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/TP.0b013e31821ab993","article-title":"Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality and healthcare costs","volume":"91","author":"Schnitzler","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib334","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jval.2014.01.001","article-title":"Projecting long-term graft and patient survival after transplantation","volume":"17","author":"Levy","year":"2014","journal-title":"Value Health"},{"key":"key20160826114108453_ref1-bib335","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7182\/pit2014710","article-title":"The cost of kidney transplant over time","volume":"24","author":"Barnieh","year":"2014","journal-title":"Prog Transplant"},{"key":"key20160826114108453_ref1-bib336","first-page":"10a","article-title":"Renal function improves significantly after early cyclosporine withdrawal in sirolimus-treated renal transplant recipients: 3-year results of the Rapamune Maintenance Regimen (RMR) trial","volume":"14","author":"Oberbauer","year":"2003","journal-title":"JASN"},{"key":"key20160826114108453_ref1-bib337","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"key20160826114108453_ref1-bib338","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1477-7525-10-139","article-title":"Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study","volume":"10","author":"Neri","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"key20160826114108453_ref1-bib339","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000360027","article-title":"UK Renal Registry 16th annual report. Chapter 8. Survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses","volume":"125","author":"Pruthi","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"key20160826114108453_ref1-bib340","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1523-1755.2002.00424.x","article-title":"Post-transplant renal function in the first year predicts long-term kidney transplant survival","volume":"62","author":"Hariharan","year":"2002","journal-title":"Kidney Int"},{"key":"key20160826114108453_ref1-bib341","doi-asserted-by":"publisher","first-page":"CD004290","DOI":"10.1002\/14651858.cd004290.pub2","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"2","author":"Webster","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160826114108453_ref1-bib342","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib343","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib344","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/TP.0b013e3182292426","article-title":"Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients","volume":"92","author":"Wu","year":"2011","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib345","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib346","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib347","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"key20160826114108453_ref1-bib348","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/TP.0b013e318284c15b","article-title":"Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review","volume":"95","author":"Ho","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib349","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transpl Int"},{"key":"key20160826114108453_ref1-bib350","volume-title":"Secretariat Assessment Report: Advice No. 1712 Belatacept (Nulojix\u00ae)","author":"All Wales Medicines Strategy Group (AWMSG)","year":"2012"},{"key":"key20160826114108453_ref1-bib351","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.transproceed.2011.09.092","article-title":"Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation","volume":"43","author":"Gamboa","year":"2011","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib352","doi-asserted-by":"publisher","first-page":"A156","DOI":"10.1016\/j.jval.2012.03.840","article-title":"Cost-utility assessment of sirolimus versus tacrolimus for primary prevention of graft rejection in renal transplant recipients in Mexico","volume":"15","author":"Rely","year":"2012","journal-title":"Value Health"},{"key":"key20160826114108453_ref1-bib353","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.transproceed.2005.11.092","article-title":"Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients","volume":"38","author":"Niemczyk","year":"2006","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib354","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/TP.0b013e3181661695","article-title":"Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation","volume":"85","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib355","volume-title":"National Organ Retrieval Service: Service Evaluation","author":"NHS Blood and Transplant (NHSBT)","year":"2013"},{"key":"key20160826114108453_ref1-bib356","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/ndt\/gfh505","article-title":"Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study","volume":"19","author":"Butler","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"key20160826114108453_ref1-bib357","doi-asserted-by":"publisher","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technol Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20160826114108453_ref1-bib358","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1185\/030079905X65277","article-title":"Characterisation and comparison of health-related quality of life for patients with renal failure","volume":"21","author":"Lee","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"key20160826114108453_ref1-bib359","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.transproceed.2010.02.083","article-title":"Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus","volume":"42","author":"Tedesco-Silva","year":"2010","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib360","first-page":"46","article-title":"Concentration-controlled everolimus with reduced cyclosporine concentration in de novo renal transplant recipients: efficacy results at 24 months","volume":"11","author":"Tedesco-Silva","year":"2011","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib361","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00007890-200407271-00241","article-title":"The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus","volume":"78","author":"Dean","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib362","volume-title":"Organ Donation for Transplantation: Costing Report. Implementing NICE Guidance","author":"National Institute for Health and Care Excellence (NICE)","year":"2011"},{"key":"key20160826114108453_ref1-bib363","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s11136-011-9905-8","article-title":"Impaired renal function is associated with worse self-reported outcomes after kidney transplantation","volume":"20","author":"Neri","year":"2011","journal-title":"Qual Life Res"},{"key":"key20160826114108453_ref1-bib364","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1185\/03007995.2014.898140","article-title":"A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients","volume":"30","author":"Goring","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key20160826114108453_ref1-bib365","first-page":"406","article-title":"Modeled long term projections of clinical outcomes from BENEFIT and BENEFIT-EXT","volume":"12","author":"Levy","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib366","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.diabres.2004.01.002","article-title":"The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications","volume":"67","author":"Currie","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"key20160826114108453_ref1-bib367","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1399-3089.2010.00586.x","article-title":"A health-economic analysis of porcine islet xenotransplantation","volume":"17","author":"Beckwith","year":"2010","journal-title":"Xenotransplantation"},{"key":"key20160826114108453_ref1-bib368","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ndt\/gfp174","article-title":"The cost-effectiveness of induction immunosuppression in kidney transplantation","volume":"24","author":"Morton","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib369","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014","edition":"67 ed."},{"key":"key20160826114108453_ref1-bib370","volume-title":"eMit National Database (2014\/06): Drugs and Pharmaceutical Electronic Market Information (eMit)","author":"Commercial Medicines Unit","year":"2014"},{"key":"key20160826114108453_ref1-bib371","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3111\/13696998.2011.579213","article-title":"Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK","volume":"14","author":"Beaudet","year":"2011","journal-title":"J Med Econ"},{"key":"key20160826114108453_ref1-bib372","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/ndt\/gfm870","article-title":"The cost of renal dialysis in a UK setting: a multicentre study","volume":"23","author":"Baboolal","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib373","volume-title":"Organ Donation for Transplantation: Improving Donor Identification and Consent Rates for Deceased Organ Donation","author":"National Institute for Health and Care Excellence (NICE)","year":"2011"},{"key":"key20160826114108453_ref1-bib374","volume-title":"Organ Donation for Transplantation. Costing Report. Implementing NICE Guidance","author":"National Institute for Health and Clinical Excellence","year":"2011"},{"key":"key20160826114108453_ref1-bib375","volume-title":"Health Survey for England 2012","author":"Craig","year":"2013"},{"key":"key20160826114108453_ref1-bib376","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20160826114108453_ref1-bib377","author":"NHS Blood and Transplant","journal-title":"The UK Transplant Registry Standard Data Set (2007\u20132012)"},{"key":"key20160826114108453_ref1-bib378","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2215\/CJN.04681107","article-title":"Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival","volume":"3","author":"Cole","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib379","volume-title":"Belatacept Micro-costing Model","author":"Ling","year":"2011"},{"key":"key20160826114108453_ref1-bib380","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00125-005-1717-3","article-title":"Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)","volume":"48","author":"Clarke","year":"2005","journal-title":"Diabetologia"},{"key":"key20160826114108453_ref1-bib381","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"key20160826114108453_ref1-bib382","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000360022","article-title":"UK Renal Registry 16th Annual Report. Chapter 3. Demographic and biochemistry profile of kidney transplant recipients in the UK in 2012: national and centre-specific analyses","volume":"125","author":"Pruthi","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"key20160826114108453_ref1-bib383","volume-title":"Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and population of Cost-Effectiveness Models","author":"Kaltenthaler","year":"2011"},{"issue":"38","key":"key20160826114108453_ref1-bib384","doi-asserted-by":"publisher","DOI":"10.3310\/hta13380","article-title":"The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model","volume":"13","author":"Bond","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20160826114108453_ref1-bib385","volume-title":"UK Renal Registry Report 2005: 8th Annual Report of the Renal Association","author":"Ansell","year":"2005"},{"key":"key20160826114108453_ref1-bib386","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/TP.0b013e31827a938f","article-title":"Risks and benefits of preemptive second kidney transplantation","volume":"95","author":"Johnston","year":"2013","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib387","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/TP.0b013e318199c1c7","article-title":"Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation","volume":"87","author":"Opelz","year":"2009","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib388","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1053\/ajkd.2002.31996","article-title":"A thirty per cent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure","volume":"39","author":"Kasiske","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20160826114108453_ref1-bib389","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/01.TP.0000061602.03327.E2","article-title":"Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation","volume":"75","author":"Meier-Kriesche","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib390","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.tp.0000188135.04259.2e","article-title":"Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant","volume":"81","author":"Salvadori","year":"2006","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib391","volume-title":"Statistical Methodology and Risk-Adjustment for Survival Rate Estimation","author":"UK Transplant Registry","year":"2011"},{"key":"key20160826114108453_ref1-bib392","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1111\/j.1600-6143.2012.04226.x","article-title":"Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report","volume":"12","author":"Opelz","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib393","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/ajt.12313","article-title":"Association between steroid dosage and death with a functioning graft after kidney transplantation","volume":"13","author":"Opelz","year":"2013","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib394","first-page":"ii312","article-title":"Survival after renal transplant failure: a UK Renal Registry analysis","volume":"27","author":"Webb","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key20160826114108453_ref1-bib395","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients","volume":"3","author":"Woodward","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib396","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1034\/j.1600-6143.2003.00133.x","article-title":"Prevalence and management of anemia in renal transplant recipients: a European survey","volume":"3","author":"Vanrenterghem","year":"2003","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib397","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/TP.0b013e3181c7dc99","article-title":"Factors affecting graft and patient survival after live donor kidney transplantation in the UK","volume":"89","author":"Fuggle","year":"2010","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib398","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(10)60827-6","article-title":"Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study","volume":"376","author":"Summers","year":"2010","journal-title":"Lancet"},{"key":"key20160826114108453_ref1-bib399","volume-title":"Health Survey for England \u2013 2012","author":"Health and Social Care Information Centre (HSCIC)","year":"2013"},{"key":"key20160826114108453_ref1-bib400","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key20160826114108453_ref1-bib401","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1524-4733.2007.00308.x","article-title":"Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis","volume":"11","author":"Liem","year":"2008","journal-title":"Value Health"},{"key":"key20160826114108453_ref1-bib402","doi-asserted-by":"publisher","first-page":"E554","DOI":"10.1111\/ctr.12198","article-title":"Health-related quality of life in kidney transplant patients with diabetes","volume":"27","author":"Dukes","year":"2013","journal-title":"Clin Transplant"},{"key":"key20160826114108453_ref1-bib403","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"key20160826114108453_ref1-bib404","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00005650-200503000-00004","article-title":"Valuations of EQ-5D health states: are the United States and United Kingdom different?","volume":"43","author":"Johnson","year":"2005","journal-title":"Med Care"},{"key":"key20160826114108453_ref1-bib405","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1524-4733.2005.00046.x","article-title":"The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects","volume":"8","author":"Currie","year":"2005","journal-title":"Value Health"},{"key":"key20160826114108453_ref1-bib406","doi-asserted-by":"publisher","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLOS Med"},{"key":"key20160826114108453_ref1-bib407","volume-title":"Unit Costs of Health and Social Care 2014","author":"Curtis","year":"2014"},{"key":"key20160826114108453_ref1-bib408","volume-title":"Kidney Transplant Protocol","author":"Moore","year":"2012"},{"key":"key20160826114108453_ref1-bib409","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jmv.23539","article-title":"High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy","volume":"85","author":"Harvala","year":"2013","journal-title":"J Med Virol"},{"key":"key20160826114108453_ref1-bib410","volume-title":"Preliminary Report: PORTRAIT Database Study: Cardiff","author":"Ling","year":"2011"},{"key":"key20160826114108453_ref1-bib411","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.transproceed.2010.05.151","article-title":"Molecular epidemiology of Epstein\u2013Barr virus in adult kidney transplant recipients","volume":"42","author":"Cavallo","year":"2010","journal-title":"Transplant Proc"},{"key":"key20160826114108453_ref1-bib412","volume-title":"Reference Costs Guidance 2013\u201314","author":"Department of Health (DH)","year":"2014"},{"key":"key20160826114108453_ref1-bib413","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib414","volume-title":"Immunosuppression Following Renal Transplantation","author":"Welsh Renal Clinical Network","year":"2012"},{"key":"key20160826114108453_ref1-bib415","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabet Med"},{"key":"key20160826114108453_ref1-bib416","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1464-5491.2011.03429.x","article-title":"Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus","volume":"29","author":"Davies","year":"2012","journal-title":"Diabet Med"},{"key":"key20160826114108453_ref1-bib417","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1136\/bmj.39545.585289.25","article-title":"Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis","volume":"336","author":"Gillies","year":"2008","journal-title":"BMJ"},{"key":"key20160826114108453_ref1-bib418","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1464-5491.2010.03040.x","article-title":"Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*","volume":"27","author":"Currie","year":"2010","journal-title":"Diabet Med"},{"key":"key20160826114108453_ref1-bib419","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme.12647","article-title":"The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)","volume":"32","author":"Alva","year":"2015","journal-title":"Diabet Med"},{"key":"key20160826114108453_ref1-bib420","volume-title":"Erythropoiesis Stimulating Agents (Epoetin and Darbepoetin) for Treating Anaemia in People with Cancer Having Chemotherapy. TA323","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160826114108453_ref1-bib421","volume-title":"Developing Robust Reference Costs for Kidney Transplants: Update","author":"NHS Kidney Care","year":"2011"},{"key":"key20160826114108453_ref1-bib422","volume-title":"Provider-to-Provider Services 2013\u20132014 Tariff","author":"University College London Hospitals","year":"2014"},{"key":"key20160826114108453_ref1-bib423","volume-title":"Therapeutic Drug Monitoring Test Repertoire","author":"Department of Biochemistry and Immunology, University Hospital of Wales"},{"key":"key20160826114108453_ref1-bib424","volume-title":"HRG4\u2009+\u2009Reference Costs Code to Group","author":"National Casemix Office (NCO)","year":"2014"},{"key":"key20160826114108453_ref1-bib425","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"key20160826114108453_ref1-bib426","volume-title":"Assessing Technologies That are Not Cost-effective at a Zero Price","author":"Davis","year":"2014"},{"key":"key20160826114108453_ref1-bib427","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00007890-200407271-00690","article-title":"Long term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic) is safe in kidney transplant patients","volume":"78","author":"Salvadori","year":"2004","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib428","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X03261561","article-title":"Gaussian process modelling in conjunction with individual patient simulation modelling: a case study describing the calculation of cost-effectiveness ratios for the treatment of osteoporosis","volume":"24","author":"Stevenson","year":"2004","journal-title":"Med Decis Mak"},{"key":"key20160826114108453_ref1-bib429","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1097\/01.TP.0000090865.20886.B7","article-title":"Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen","volume":"76","author":"Irish","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib430","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1097\/01.ASN.0000095250.92361.D5","article-title":"Long-term graft survival with neoral and tacrolimus: a paired kidney analysis","volume":"14","author":"Kaplan","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib431","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.TP.0000079965.62765.1A","article-title":"Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids","volume":"76","author":"Bunnapradist","year":"2003","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib432","volume-title":"UK Renal Registry 15th Annual Report","author":"UK Renal Registry (UKRR)","year":"2012"},{"key":"key20160826114108453_ref1-bib433","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/00007890-200109150-00007","article-title":"Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure","volume":"72","author":"Johnson","year":"2001","journal-title":"Transplantation"},{"key":"key20160826114108453_ref1-bib434","volume-title":"2004 Annual Report, Transplant Data 1994\u20132003","author":"US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients","year":"2004"},{"key":"key20160826114108453_ref1-bib435","volume-title":"Rapamune Dosing Study [data on file]","author":"Surveillance Data Inc","year":"2005"},{"key":"key20160826114108453_ref1-bib436","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1600-6143.2003.00290.x","article-title":"Payment for living donor (vendor) kidneys: a cost-effectiveness analysis","volume":"4","author":"Matas","year":"2004","journal-title":"Am J Transplant"},{"key":"key20160826114108453_ref1-bib437","first-page":"14","article-title":"Measurement of quality of life in end-stage renal disease: the time trade-off approach","volume":"10","author":"Churchill","year":"1987","journal-title":"Clin Invest Med"},{"key":"key20160826114108453_ref1-bib438","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1681\/ASN.2004121059","article-title":"Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation","volume":"16","author":"Weng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key20160826114108453_ref1-bib439","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2215\/CJN.09440912","article-title":"Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States","volume":"8","author":"Tanriover","year":"2013","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20620\/hta20620.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20620\/hta20620.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:46:34Z","timestamp":1749570394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20620\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":439,"journal-issue":{"issue":"62","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["10.3310\/hta20620"],"URL":"https:\/\/doi.org\/10.3310\/hta20620","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}